DEALS

Zhong Lun Advises on Transcenta’s IPO in Hong Kong

Release time：2021-09-29 Voice Announcements

On September 29, 2021, Transcenta Holding Limited (6628.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the proceeds of approximately HK$645 million prior to the exercise of the over-allotment option. Goldman Sachs and CICC acted as joint sponsors for the offering.

Transcenta is a clinical stage biopharmaceutical company that integrates the capacities of discovery, research & development, manufacturing, and business development. It has developed a unique antibody discovery platform, the Immune Tolerance Breaking Technology Platform (IMTB).

Zhong Lun acted as the issuer’s PRC legal advisor in this offering. The Zhong Lun team was led by Anthony Zhao and William Jia and included Roy Zheng, Lindsay Zhang, etc.; and Lefan Gong advised on the ESOP design during the IPO process.

Previous：Zhong Lun Helps Ankon Win Eight STAR Market Patent Infringement Cases Next：Zhong Lun Advises on Privatization of Sogou

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists Multiple Humanoid Robot and Intelligent Equipment Science and Technology Companies and Investors in Completing Tens of Millions Yuan Financing and Investment

Zhong Lun Advises on CR Beverage’s IPO in Hong Kong

Events

Awards

Zhong Lun Advises on Transcenta’s IPO in Hong Kong